Skip to content

Restricted Cash at other companies

Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$259K-17.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$800K+60.0%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$601K+29.5%
Alkermes logo
AlkermesALKS
$0
Boston Scientific logo
Boston ScientificBSX
Corcept Therapeutics logo
Corcept TherapeuticsCORT

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.26B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s restricted cash?
Mineralys Therapeutics, Inc. (MLYS) reported restricted cash of $0 in Q1 2026.
What is the long-term trend for Mineralys Therapeutics, Inc.'s restricted cash?
Over 4 years (2021 to 2025), Mineralys Therapeutics, Inc.'s restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $50K to $0.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.